Could a Pre-Chemo drug shield bone marrow in head and neck cancer?
NCT ID NCT07679997
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This trial tests whether giving trilaciclib before chemotherapy and immunotherapy can protect bone marrow in people with advanced head and neck cancer. The goal is to reduce dangerous drops in blood cell counts, allowing patients to receive their full chemo doses on schedule. About 32 adults with recurrent or metastatic head and neck squamous cell carcinoma will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- trilaciclib
- What this could lead to
- If it works, this could help people with advanced head and neck cancer complete chemotherapy on time with fewer side effects like low blood cell counts.
- What could go wrong
- This is a small, early-phase trial with only 32 participants, so results may not apply to everyone. The drug may not reduce side effects as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD & NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI model aims to end guesswork in head and neck cancer care
- Smart radiotherapy aims to cut cancer treatment side effects
- Gut health boost may tame immunotherapy side effects in head and neck cancer
- New hope for head and neck cancer patients who Can't take chemo
- Can a PET scan predict if immunotherapy works? new study aims to find out
- New PET scan could end guesswork after head and neck cancer radiation